Translational Research Working Group developmental pathway for biospecimen-based assessment modalities

Sudhir Srivastava, Joe Gray, Brian J. Reid, Oren Grad, Addison Greenwood, Ernest T. Hawk

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

The Translational Research Working Group (TRWG) was created as a national initiative to evaluate the current status of National Cancer Institute's investment in translational research and envision its future. TheTRWG conceptualized translational research as a set of six developmental processes or pathways focused on various clinical goals. One of those pathways describes the development of biospecimen-based assays that use biomarkers for the detection, diagnosis, and prognosis of cancer and the assessment of response to cancer treatment. The biospecimen-based assessment modality pathway was conceived not as comprehensive description of the corresponding real-world processes but rather as a tool designed to facilitate movement of a candidate assay through the translational process to the point where it can be handed off for definitive clinical testing. This paper introduces the pathway in the context of prior work and discusses key challenges associated with the biomarker development process in light of the pathway.

Original languageEnglish (US)
Pages (from-to)5672-5677
Number of pages6
JournalClinical Cancer Research
Volume14
Issue number18
DOIs
StatePublished - Sep 15 2008
Externally publishedYes

Fingerprint

Translational Medical Research
Biomarkers
National Cancer Institute (U.S.)
Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Translational Research Working Group developmental pathway for biospecimen-based assessment modalities. / Srivastava, Sudhir; Gray, Joe; Reid, Brian J.; Grad, Oren; Greenwood, Addison; Hawk, Ernest T.

In: Clinical Cancer Research, Vol. 14, No. 18, 15.09.2008, p. 5672-5677.

Research output: Contribution to journalArticle

Srivastava, Sudhir ; Gray, Joe ; Reid, Brian J. ; Grad, Oren ; Greenwood, Addison ; Hawk, Ernest T. / Translational Research Working Group developmental pathway for biospecimen-based assessment modalities. In: Clinical Cancer Research. 2008 ; Vol. 14, No. 18. pp. 5672-5677.
@article{be8aa19fd00247f7adb9179a0f5fb2b6,
title = "Translational Research Working Group developmental pathway for biospecimen-based assessment modalities",
abstract = "The Translational Research Working Group (TRWG) was created as a national initiative to evaluate the current status of National Cancer Institute's investment in translational research and envision its future. TheTRWG conceptualized translational research as a set of six developmental processes or pathways focused on various clinical goals. One of those pathways describes the development of biospecimen-based assays that use biomarkers for the detection, diagnosis, and prognosis of cancer and the assessment of response to cancer treatment. The biospecimen-based assessment modality pathway was conceived not as comprehensive description of the corresponding real-world processes but rather as a tool designed to facilitate movement of a candidate assay through the translational process to the point where it can be handed off for definitive clinical testing. This paper introduces the pathway in the context of prior work and discusses key challenges associated with the biomarker development process in light of the pathway.",
author = "Sudhir Srivastava and Joe Gray and Reid, {Brian J.} and Oren Grad and Addison Greenwood and Hawk, {Ernest T.}",
year = "2008",
month = "9",
day = "15",
doi = "10.1158/1078-0432.CCR-08-1267",
language = "English (US)",
volume = "14",
pages = "5672--5677",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "18",

}

TY - JOUR

T1 - Translational Research Working Group developmental pathway for biospecimen-based assessment modalities

AU - Srivastava, Sudhir

AU - Gray, Joe

AU - Reid, Brian J.

AU - Grad, Oren

AU - Greenwood, Addison

AU - Hawk, Ernest T.

PY - 2008/9/15

Y1 - 2008/9/15

N2 - The Translational Research Working Group (TRWG) was created as a national initiative to evaluate the current status of National Cancer Institute's investment in translational research and envision its future. TheTRWG conceptualized translational research as a set of six developmental processes or pathways focused on various clinical goals. One of those pathways describes the development of biospecimen-based assays that use biomarkers for the detection, diagnosis, and prognosis of cancer and the assessment of response to cancer treatment. The biospecimen-based assessment modality pathway was conceived not as comprehensive description of the corresponding real-world processes but rather as a tool designed to facilitate movement of a candidate assay through the translational process to the point where it can be handed off for definitive clinical testing. This paper introduces the pathway in the context of prior work and discusses key challenges associated with the biomarker development process in light of the pathway.

AB - The Translational Research Working Group (TRWG) was created as a national initiative to evaluate the current status of National Cancer Institute's investment in translational research and envision its future. TheTRWG conceptualized translational research as a set of six developmental processes or pathways focused on various clinical goals. One of those pathways describes the development of biospecimen-based assays that use biomarkers for the detection, diagnosis, and prognosis of cancer and the assessment of response to cancer treatment. The biospecimen-based assessment modality pathway was conceived not as comprehensive description of the corresponding real-world processes but rather as a tool designed to facilitate movement of a candidate assay through the translational process to the point where it can be handed off for definitive clinical testing. This paper introduces the pathway in the context of prior work and discusses key challenges associated with the biomarker development process in light of the pathway.

UR - http://www.scopus.com/inward/record.url?scp=53249144494&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=53249144494&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-08-1267

DO - 10.1158/1078-0432.CCR-08-1267

M3 - Article

C2 - 18794074

AN - SCOPUS:53249144494

VL - 14

SP - 5672

EP - 5677

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 18

ER -